Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 277

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Metabolome in progression to Alzheimer's disease

Open access
Orešič, M, Hyötyläinen, T, Herukka, S-K, Sysi-Aho, M, Mattila, I, Seppänan-Laakso, T, Julkunen, V, Gopalacharyulu, P V, Hallikainen, M, Koikkalainen, J, Kivipelto, M, Helisalmi, S, Lötjönen, J, Soininen, H·2011·Translational Psychiatry

Abstract

Mild cognitive impairment (MCI) is considered as a transition phase between normal aging and Alzheimer's disease (AD). MCI confers an increased risk of developing AD, although the state is heterogeneous with several possible outcomes, including even improvement back to normal cognition. We sought to determine the serum metabolomic profiles associated with progression to and diagnosis of AD in a prospective study. At the baseline assessment, the subjects enrolled in the study were classified into three diagnostic groups: healthy controls (n=46), MCI (n=143) and AD (n=47). Among the MCI subjects, 52 progressed to AD in the follow-up. Comprehensive metabolomics approach was applied to analyze baseline serum samples and to associate the metabolite profiles with the diagnosis at baseline and in the follow-up. At baseline, AD patients were characterized by diminished ether phospholipids, phosphatidylcholines, sphingomyelins and sterols. A molecular signature comprising three metabolites was identified, which was predictive of progression to AD in the follow-up. The major contributor to the predictive model was 2,4-dihydroxybutanoic acid, which was upregulated in AD progressors (P=0.0048), indicating potential involvement of hypoxia in the early AD pathogenesis. This was supported by the pathway analysis of metabolomics data, which identified upregulation of pentose phosphate pathway in patients who later progressed to AD. Together, our findings primarily implicate hypoxia, oxidative stress, as well as membrane lipid remodeling in progression to AD. Establishment of pathogenic relevance of predictive biomarkers such as ours may not only facilitate early diagnosis, but may also help identify new therapeutic avenues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tp.2011.55

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 277

Metadata

Authors
Orešič, M., Hyötyläinen, T., Herukka, S.-K., Sysi-Aho, M., Mattila, I., Seppänan-Laakso, T., Julkunen, V, Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J., Kivipelto, M., Helisalmi, S., Lötjönen, J., & Soininen, H.
Venue
Translational Psychiatry
Published
2011-12-13
Volume
1
Issue
12
Pages
e57-e57
ISSN
2158-3188 (ISSN-L)
OpenAlex
W1981686145
Cited by
277
References
65
FWCI
12.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolome in progression to Alzheimer's disease. https://app.cochat.ai/papers/10.1038/tp.2011.55
The paper
Orešič, M., Hyötyläinen, T., Herukka, S.-K., Sysi-Aho, M., Mattila, I., Seppänan-Laakso, T., Julkunen, V, Gopalacharyulu, P. V., Hallikainen, M., Koikkalainen, J., Kivipelto, M., Helisalmi, S., Lötjönen, J., & Soininen, H. (2011). Metabolome in progression to Alzheimer's disease. Translational Psychiatry. https://doi.org/10.1038/tp.2011.55

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.